.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech plan to list on the Nasdaq under the symbolic representation "BIOA," according to papers submitted with the Stocks and also Exchange Percentage. The company has not publicly discussed an assumed financial amount for the offering.The clinical-stage provider touts lead applicant azelaprag, a by mouth provided tiny particle slated to enter phase 2 screening in combination along with semaglutide-- offered through Novo Nordisk under brand name Wegovy for weight reduction-- in the initial one-half of following year. Semaglutide is actually also offered as Ozempic and Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually developed to combine well with GLP-1 drugs, improving fat burning while keeping muscular tissue mass. The investigational medication was actually found to become well-tolerated among 265 people across 8 period 1 trials, according to BioAge.Previously, BioAge achieved the help of Lilly to manage a trial incorporating azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetic issues as Mounjaro and also Zepbound for effective weight loss. The partners are currently administering a period 2 trial of azelaprag as well as tirzepatide, along with topline outcomes assumed in the third quarter of 2025.The biotech is additionally planning an insulin sensitiveness proof-of-concept test assessing azelaprag as a monotherapy in the very first one-half of following year to sustain potential evidence development. Moreover, the firm considers to ask the FDA for authorization in the 2nd one-half of 2025 to launch human screening for an NLRP3 inhibitor targeting metabolic diseases as well as neuroinflammation.BioAge's anticipated move to the general public market adheres to a minor uptick in planned biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the current IPO landscape is a "combined picture," with high-grade providers still debuting on the general public markets, only in minimized amounts, depending on to PitchBook.